News | August 26, 2025
Merck presents new data on cardiovascular disease at ESC Congress 2025
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Guidelines aim to establish state-regulated veterinary blood banks
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Inclacumab was generally well tolerated in THRIVE-131
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated
